outperform price
best yet come
outlin macro factor brand/ invest
initi coupl easi comp pave way
sale earn ramp
momentum carri well
fewer think colgat broken question
pivot onto whether cl prove sustain
double-digit ep grower start think ye
colgat compet structur attract categori
management also focus recharg alway
advantag busi oral care hill build
reiter outperform rate rais pt per
cl share assum ep
initi reactiv core start
colgat total earli new sf version account
retail volum total franchis
still mix new old product
shelv therefor toothpast sale share build
 expand key market brazil
hill scienc diet new premium line hit pet
specialti retail shelv
price stick
perhap import insight colgat result
volum price grow tandem
first time year balanc reflect part better
macro brazil part better execut pivot
premium toothpast elmex colgat total sf
recal two-third price alreadi place
well accept work
expect competit specif pg follow crest
still promot brazil move inconsist
pg bigger pictur grow profit brazil
key enterpris market new structure/ strategi
emerg market rebound brazil india
deliv continu deliv continu
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
there difficulti separ aspect colgat
under-perform macro-driven exampl brazil consumer-
driven india india reflect consum shift natur
address success colgat ayurveda line vedshakti
china declin reflect wholesal destock amplifi
within baba taobao marketplac run parallel tmall
destock could prolong anoth quarter real issu
digit busi model potenti premium cl-china
earli news realli good oral care extens beyond colgat
therapeut earli news realli good roll-out elmex cl premium
swiss line brazil pharmaci channel retail format consolid
gain market share hypermarket like carrefour also drive trade-up
indic loral unilev
natur tom main alreadi over-index amazon
question whether colgat franchis stretch natur outsid india
russia
new on-line busi model e-commerce sale back
hill new on-line platform vet channel
share gain colgat franchis although still under-index page
impact currenc commod abat page
exhibit market share on-line vs off-lin colgat toothpast under-index e-commerce amazon
exhibit there mix new/ old colgat total retail shelv upgrad sf version account total franchis volum
date
exhibit new colgat total retail premium prior version
tom main
exhibit cl-basket commod price vs vs chang gm bp
valu equiti
valu equiti
rel stapl xlp
arriv target per cl share base rel intrins valuat methodolog
discount cash flow model point fair valu per share use wacc
growth termin valu base project ep growth
target impli forward price-to-earnings premium today xlp stapl sector
pt impli regress mean share trade rang re-rat cl share
histor averag predic convict health global oral care market
colgat capac recalibr portfolio busi model restart market share gain
widen leadership believ challeng pressur cl valuat structur
expens deal street fear like manag restructur save
back-end load cl afford higher reinvest power
there limit downsid risk given cl trade one standard deviat trade averag vs stapl
sector model assum improv macro environ brazil key profit center firm colgat
success diversifi portfolio natur therapeut oral care howev greatest risk stem increas
competit busi outsid oral care home care person care categori colgat lack financi
incent reinvest structur part cl person care busi becom less attract colgat person care
busi compos region brand miss structur premium categori
articl articl
time dissemin april
analyst yutong zhou javier escalant robert ottenstein primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
